about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesStructural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificityDeveloping dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxideOn the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporineDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersNavigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's DiseaseBreaking the Spell: Combating Multidrug Resistant 'Superbugs'Hydrophobicity and charge shape cellular metabolite concentrationsRational approaches to improving selectivity in drug designStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewMetabolomics and systems pharmacology: why and how to model the human metabolic network for drug discoveryTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesSanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current UsesDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesDrug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitorsDrug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavirDrug Promiscuity in PDB: Protein Binding Site Similarity Is KeyStructural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congenersBiochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug targetLigand-target prediction by structural network biology using nAnnoLyzeVNP: Interactive Visual Network Pharmacology of Diseases, Targets, and DrugsExploiting genomic knowledge in optimising molecular breeding programmes: algorithms from evolutionary computingBeyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancersDistribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discoveryNon-monotonic dynamics and crosstalk in signaling pathways and their implications for pharmacologyWinning a Won Game: Caffeine Panacea for Obesity SyndemicLarge-scale prediction of drug-target relationshipsTinnitus: network pathophysiology-network pharmacology.Characterizing protein domain associations by Small-molecule ligand bindingIngestion-controlling network: what's language got to do with it?How promiscuous are pharmaceutically relevant compounds? A data-driven assessment.Novel paradigms for drug discovery: computational multitarget screeningPotential strategies for increasing drug-discovery productivity.Synthesis of unprecedented scaffold diversity.Exploring a structural protein-drug interactome for new therapeutics in lung cancerWhy is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?Diversity-oriented synthesis of macrocyclic peptidomimetics.Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
P2860
Q24273350-A85490BE-EF90-43B8-AB14-1B276A67C621Q24289511-71CB2045-0853-40BD-8D59-ACDB26A60F0CQ24298026-F4F91D27-7E48-494E-B716-F37B90CA7BB1Q24321779-CFCE7835-88D4-49EB-9D62-93A0DF7D3015Q24642110-3C40FDF7-B7D2-459E-AC8B-06611A91C06BQ26748728-2F4E3BEB-B9E3-4BD9-A3C0-DFE04C551D45Q26748936-509C3500-6235-4282-B717-EFC90669544DQ26765868-27CA2F47-6A6C-4C41-B2B3-214932FCB5A2Q26864217-C80B71FB-E573-41D5-A9F0-4D5DC34DB18BQ26865357-2D9C2544-1B76-4527-BD29-6EA7E8EC530DQ27008867-FCC66EB5-9B0F-4B33-912D-08D75C73129BQ27144251-92F431F8-53E6-4C2A-AB1E-031C02982D20Q27652488-F19FFA19-DFE9-4D63-9FCD-BD5EAE44AD05Q28077612-C8C7D3C0-010C-4496-ADDB-A5740B55D426Q28305100-21D4BC54-C47D-4E43-9365-12C94C453732Q28388335-9E982449-FBA3-4979-8BBB-96F27969C93FQ28475474-8B9F2FB1-F921-49A7-AE2C-5D4051B82524Q28477930-AE1D5426-7EC8-4B08-85FE-F4CED1FAC2FEQ28534178-3A27C184-6A46-42D6-9E7B-5AAC09896C80Q28539094-4D4DFD08-246F-4E58-9AB8-0CE97A04CD16Q28545065-43893F1B-CE63-40F4-8B80-074109CD94BBQ28545126-827ED44B-EEB1-4517-81B7-14D1EAB39481Q28659025-023D0C46-63F5-48BE-ABB2-B472B2CA44FCQ28710543-1277C075-7530-471B-B34A-FABCA18053F6Q28743513-252E5897-9709-4AF8-BC0A-63E76B997819Q28754659-8975A9F8-CEE5-4D7F-85DC-FD7F16722F29Q28817451-82F01A60-6B79-47F3-8C6D-AA849D96C45DQ29540785-5F9DFB0D-1507-494B-810F-6D58DE40A1C7Q30002408-D96B33EA-1F67-4097-BA46-6BC654B01E01Q30412371-2A926F7B-B980-4076-A511-FA9AA8187F53Q30431581-8E8D1840-1D6D-4863-81E3-D51A59F3C5D0Q30471332-1DCF8F9D-275D-4B3D-8310-16899C05FE9AQ30574444-C5DDE070-068A-433C-92C6-17CE839AC7BDQ30662767-29C875F6-FD77-416E-BDFA-EF80C6F450F1Q31154360-30EA58F8-F4A3-4855-A108-4FA7BF99C682Q33399155-772BC4EC-1083-4DFB-9E1D-9BF7B61C6E1CQ33593907-B93F1D01-A4EE-4E19-B945-60C4B2ACBC55Q33657605-4FE97051-5304-46BF-BDA4-19284F1D4C13Q33839090-0A16966F-4090-4D1E-8816-F4639BCAFAB7Q33845886-C9D845B3-48A4-4602-A6DF-B80DFFC17565
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Can we rationally design promiscuous drugs?
@ast
Can we rationally design promiscuous drugs?
@en
Can we rationally design promiscuous drugs?
@nl
type
label
Can we rationally design promiscuous drugs?
@ast
Can we rationally design promiscuous drugs?
@en
Can we rationally design promiscuous drugs?
@nl
prefLabel
Can we rationally design promiscuous drugs?
@ast
Can we rationally design promiscuous drugs?
@en
Can we rationally design promiscuous drugs?
@nl
P3181
P1476
Can we rationally design promiscuous drugs?
@en
P2093
Jonathan S Mason
P304
P3181
P356
10.1016/J.SBI.2006.01.013
P407
P577
2006-02-01T00:00:00Z